[ad_1]
Australian biotech company Ena Respiratory has announced that a nasal spray that was originally developed to boost the immune system against colds and flu may also be effective in fighting the emerging corona virus.
One study found that INNA-051 spray reduced the growth of the Corona virus, which causes Covid-19 disease, in animals by 96%.
According to the study by the Public Health Agency of England, INNA-051 spray has been shown to be effective in “drastically reducing the growth levels of the Covid-19 virus in the nose and throat” and reducing viral reproduction by 96% in rodents.
In a statement, the Australian company stated that the spray works by stimulating the immune system before infection with the disease, and human trials are expected to begin in a few weeks.
Company officials expected the drug to achieve a similar response in humans, including silent carriers of the disease. Specialists said they were surprised by the effectiveness of the treatment, especially as it clears the virus in the early stages in the nose and throat.
According to the release, human trials are scheduled to take less than four months, but the company is now awaiting regulatory approval.
The statement indicated that if the nasal spray were effective, it would complement the final vaccine, indicating that “it will be taken once or twice a week.”
The Ena Respiratory company indicated that the inhaler was in development before the appearance of the Corona virus, with the aim of strengthening immunity against influenza, and with the outbreak of the pandemic, officials reoriented their efforts to make the inhaler effective in the fight against Covid-19.
“INNA-051 uses the unspecified innate immune response, which means that it is effective against a wide range of viruses,” said Chris Smith, director of the Ena Respiratory Board.
The study involves Australian research organizations, the Hunter Institute for Medical Research and the University of Melbourne.
"); //}, 3000);}}); //$(window).bind('scroll '); $ (window) .scroll (function () {if (alreadyLoaded_facebookConnect == false) {alreadyLoaded_facebookConnect = true ; // $ (window) .unbind ('scroll'); // console.log ("scroll loaded"); (function (d, s, id) {var js, fjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = id; js.async = true; js._https = true; js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322"; fjs.parentNode.insertBefore (js, fjs); } (document, 'script', 'facebook-jssdk')); // pre_loader (); // $ (window) .unbind ('mousemove'); // setTimeout (function () {// $ ('# boxTwitter'). html ("Tweets from @tayyar_org"); //}, 3000); var scriptTag = document.createElement (" script "); scriptTag.type =" text / javascript "scriptTag.src =" https://news.google.com/scripts/social. js "; scriptTag.async = true; document.getElementsByTagName (" head ")[0].appendChild (scriptTag); (function () {$ .getScript ("https://news.google.com/scripts/social.js", function () {});}); }}); //$(window).load(function () {// setTimeout (function () {// // add the returned content to a newly created script tag // var se = document.createElement ('script'); / / se.type = "text / javascript"; // //se.async = true; // se.text = "setTimeout (function () {pre_loader ();}, 5000);"; // document. getElementsByTagName ('body')[0].appendChild (se); //}, 5000); //});
[ad_2]
